Tao Yu

Dr. Tao Yu

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 August 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
LXLili Xu
Lili Xu
LDLixiang Deng
Lixiang Deng
ZHZhenzhen Huang
Zhenzhen Huang
KCKuan Cheng
Kuan Cheng
YXYe Xu
Ye Xu
JGJunbo Ge
Junbo Ge
Background: Left ventricular thrombus (LVT) is a serious complication associated with cardiomyopathy and impaired left ventricular (LV) systolic function. Patients with LVT resolution remain at risk for recurrence and subsequent thromboembolism. However, the factors influencing the recurrence of LVT are not yet fully understood. This study aimed to identify the risk factors and clinical outcomes related to LVT recurrence and to improve follow-up strategies and treatment options. Methods and results: We retrospectively investigated patients diagnosed with LVT on transthoracic echocardiography from January 2018 to April 2021 in Zhongshan Hospital Fudan University. All patients received anticoagulant therapy for more than 6 months and underwent at least two follow-up transthoracic echocardiograms. No statistically significant differences were observed in baseline characteristics between the LVT recurrence and non-recurrence group, regarding gender, age, diabetes, hyperlipidemia, renal function, previous stroke history, other underlying medical conditions, ejection fraction, or left ventricular diameter. Patients in the recurrence group exhibited a higher prevalence of previous myocardial infarction and percutaneous coronary intervention compared to the non-recurrence group (84.6% vs 61.1%, p = 0.03; 76.9% vs 52.8%, p = 0.03). Additionally, patients in the recurrence group tended to have more ventricular aneurysms (50.0% vs 22.2%, p = 0.008) and larger previous thrombus sizes (27.7 ± 12.6 vs 21.4 ± 9.1 mm, p = 0.008) compared to those in the non-recurrence group. Multivariate logistic regression analysis indicated that the longitudinal diameter of the LVT was an independent risk factor for LVT recurrence (OR 1.058, 95% CI 1.003-1.115, p = 0.04). ROC curve analysis revealed an area under the curve of 0.647 for the longitudinal diameter of LVT, with an optimal cut-off value of 23.5mm, a sensitivity of 62%, and a specificity of 64%. After a follow-up of 3.0 ± 2.5 years, the incidence of non-fatal myocardial infarction and major adverse cardiovascular events (MACE) in the recurrence group was significantly higher than in the non-recurrence group [non-fatal myocardial infarction: 3 (11.5%) vs 1 (1.4%), p = 0.02; MACE: 7 (26.9%) vs 7 (9.7%), p = 0.01]. No statistically significant differences were found in bleeding events, systemic embolism, or all-cause death between the two groups. Conclusions: Our study indicates that a history of myocardial infarction, the presence of ventricular aneurysm, and larger thrombus diameter are significant factors influencing LVT recurrence. Furthermore, the longitudinal diameter of the thrombus is identified as an independent risk factor for recurrence following resolution. We recommend patients with a LVT diameter greater than 23.5 mm consider extending their anticoagulant therapy to mitigate the risk of recurrence.

Verified
Journal Article
Open access
PDF file
LXLili Xu
Lili Xu
LDLixiang Deng
Lixiang Deng
ZHZhenzhen Huang
Zhenzhen Huang
KCKuan Cheng
Kuan Cheng
YXYe Xu
Ye Xu
JGJunbo Ge
Junbo Ge
Background: Left ventricular thrombus (LVT) is a serious complication associated with cardiomyopathy and impaired left ventricular (LV) systolic function. Patients with a resolved LVT remain at risk for recurrence and subsequent thromboembolism. However, the factors influencing the recurrence of LVT are not yet fully understood. The aim of this study was to identify the risk factors and clinical outcomes related to LVT recurrence and to improve follow-up strategies and treatment options. Methods and results: We retrospectively investigated patients confirmed to have a resolved LVT by transthoracic echocardiography from January 2018 to April 2021 at Zhongshan Hospital Fudan University. All patients received anticoagulant therapy for more than 6 months and underwent at least two follow-up transthoracic echocardiograms. No statistically significant differences were observed in baseline characteristics between the LVT recurrence and non-recurrence groups, including gender, age, diabetes, hyperlipidemia, renal function, previous stroke history, other underlying medical conditions, ejection fraction, or left ventricular diameter. Patients in the recurrence group exhibited a higher prevalence of previous myocardial infarction and percutaneous coronary intervention compared to the non-recurrence group (84.6% vs. 61.1%, p = 0.03; 76.9% vs. 52.8%, p = 0.03). Additionally, patients in the recurrence group tended to have more ventricular aneurysms (50.0% vs. 22.2%, p = 0.008) and larger previous thrombus sizes (27.7 ± 12.6 vs. 21.4 ± 9.1 mm, p = 0.008) compared to those in the non-recurrence group. Multivariate logistic regression analysis indicated that the longitudinal diameter of the LVT was an independent risk factor for LVT recurrence (OR 1.058, 95% CI 1.003–1.115, p = 0.04). ROC curve analysis revealed an area under the curve of 0.647 for the longitudinal diameter of the LVT, with an optimal cut-off value of 23.5 mm, a sensitivity of 62%, and a specificity of 64%. After a follow-up duration of 3.0 ± 2.5 years, the incidence of non-fatal myocardial infarction and major adverse cardiovascular events (MACEs) in the recurrence group was significantly higher than that in the non-recurrence group [non-fatal myocardial infarction: 3 (11.5%) vs. 1 (1.4%), p = 0.02; MACE: 7 (26.9%) vs. 7 (9.7%), p = 0.01]. No statistically significant differences were found in bleeding events, systemic embolism, or all-cause death between the two groups. Conclusions: Our study indicates that a history of myocardial infarction, the presence of ventricular aneurysm, and a larger thrombus diameter are significant factors influencing LVT recurrence. Furthermore, the longitudinal diameter of the thrombus is identified as an independent risk factor for recurrence following resolution. The threshold for LVT diameter requiring extended anticoagulation and the required duration of anticoagulation need to be confirmed in future studies.

Verified
Journal Article
Open access
PDF file
YPYang Pang
Yang Pang
TYTao Yu
Tao Yu
YXYe Xu
Ye Xu
QCQingxing Chen
Qingxing Chen
YLYunlong Ling
Yunlong Ling
WZWenqing Zhu
Wenqing Zhu
Background: Pulmonary vein isolation (PVI) is a foundational treatment for persistent atrial fibrillation (PeAF), but the effectiveness of adding posterior wall isolation (PWI) and selective complex fractionated atrial electrogram (CFAE) ablation in the roof and anterior wall remains debated. The potential of these additional ablation techniques to improve long-term outcomes for PeAF patients is still uncertain. Methods: This retrospective study included 151 PeAF patients who underwent first-time catheter ablation at our center. The choice of ablation strategy was based on the operator’s clinical judgment, taking into account the patient’s specific condition and anatomical features. Patients were divided into two groups: the PVI group, which received PVI alone, and the modified PWI (MPWI) group, which received PVI along with additional PWI and selective CFAEs ablation in the roof and anterior wall. The primary endpoint was the absence of atrial arrhythmia lasting more than 30 s, without antiarrhythmic drugs, at 12 months. Results: At the 12-month follow-up, 77.3% of the patients in the MPWI group and 52.1% of the patients in the PVI group remained in sinus rhythm without an atrial arrhythmia recurrence (p = 0.001). The BIC-based Cox regression analysis identified the ablation strategy and atrial fibrillation (AF) duration as independent predictors of recurrence across the cohort. It was found that MPWI significantly reduced the risk of recurrence, while a longer AF duration increased it. In the MPWI group, AF duration, left ventricular internal diameter in systole (LVIDs), and moderate or greater tricuspid regurgitation were independent predictors of recurrence. In the PVI group, only the left atrial low voltage area (LVA) index was a significant predictor. Conclusion: The addition of PWI and selective CFAE ablation to PVI significantly improves 12-month arrhythmia-free survival compared to PVI alone, demonstrating the superiority of this combined approach in improving long-term outcomes for patients with persistent AF.

Verified
Journal Article
Open access
PDF file
YLYunlong Ling
Yunlong Ling
TYTao Yu
Tao Yu
YXYe Xu
Ye Xu
QWQuan Wan
Quan Wan
YPYang Pang
Yang Pang
JGJunbo Ge
Junbo Ge
Background: Intracardiac echocardiography (ICE)-guided percutaneous endocardial septal ablation (PESA) is a promising alternative strategy for symptomatic hypertrophic obstructive cardiomyopathy (HOCM). However, the extent of left ventricular outflow tract gradient (LVOTG) reduction after PESA varies considerably among patients, and reliable echocardiographic predictors of procedural efficacy remain unclear. We aimed to identify echocardiographic predictors of procedural efficacy and to describe our ablation strategy. Methods: We retrospectively analyzed 30 consecutive symptomatic HOCM patients who underwent ICE-guided PESA. The primary endpoint was the absolute change in resting LVOTG from baseline to the 1-year follow-up; a key secondary endpoint was significant gradient reduction, defined as a ≥50% decrease in resting LVOTG. Associations between LVOTG reduction and baseline echocardiographic parameters, particularly anterior mitral leaflet length (AMLL) and interventricular septal thickness (IVST), were evaluated. Results: At 1 year, the mean resting LVOTG decreased from 86.03 ± 24.30 mmHg to 41.43 ± 18.49 mmHg (p < 0.001). For the key secondary endpoint (≥50% resting LVOTG reduction), AMLL was the only variable associated with the outcome in the prespecified multivariable logistic model (OR per 1 mm increase: 0.429; p = 0.006), with consistent findings in a Firth penalized logistic regression sensitivity analysis. ROC analysis identified an exploratory AMLL cutoff of approximately 29 mm (AUC 0.920; sensitivity 90%; specificity 80%). In the continuous-outcome analysis, each 1 mm increase in AMLL corresponded to approximately 4.3 mmHg less LVOTG reduction (β = −4.32; p < 0.001). Thinner IVST was not significantly associated with greater procedural efficacy (p = 0.052), suggesting a potential thickness-dependent limit that warrants further investigation. Conclusions: ICE-guided PESA effectively reduces LVOT obstruction in HOCM. Shorter AMLL predicted greater LVOT gradient reduction in this exploratory cohort, and a Youden-derived AMLL cutoff of approximately 29 mm may help identify patients who are more likely to achieve substantial gradient reduction.